<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00014612</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-10981-22023</org_study_id>
    <nct_id>NCT00014612</nct_id>
  </id_info>
  <brief_title>Comparison of Complete Axillary Lymph Node Dissection With Axillary Radiation Therapy in Treating Women With Invasive Breast Cancer</brief_title>
  <acronym>AMAROS</acronym>
  <official_title>After Mapping Of The Axilla: Radiotherapy Or Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ALMANAC Trialists Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Borstkanker Onderzoeksgroup Nederland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be a less
      invasive treatment and cause fewer side effects than complete axillary lymph node dissection.
      It is not yet known which treatment is more effective for invasive breast cancer.

      PURPOSE: Randomized phase III trial to compare the effectiveness of complete axillary lymph
      node dissection with that of axillary radiation therapy in treating women who have invasive
      breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the regional control of the axilla obtained by complete axillary lymph node
           dissection vs axillary radiotherapy in sentinel lymph node-positive women with operable
           invasive breast cancer.

        -  Determine whether local and regional axillary control can be obtained without axillary
           lymph node dissection in sentinel lymph node-negative women.

        -  Compare the axillary 5-year recurrence-free survival of these patients treated with
           these regimens.

        -  Compare the morbidity of patients treated with these regimens.

        -  Compare the quality of life of these patients treated with these regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      participating center and type of breast surgery (conservation vs total mastectomy). Patients
      are randomized to 1 of 2 treatment arms.

      Patients are given an injection of a tracer and undergo lymphoscintigraphy 2-3 hours later to
      identify the sentinel lymph node. Within 24 hours after lymphoscintigraphy, patients undergo
      wide local excision of the tumor or mastectomy after the sentinel node is removed. If no
      sentinel node is found or metastasis is found in a nonsentinel node, patients undergo
      complete axillary lymph node dissection (ALND) regardless of randomization. Sentinel
      node-negative patients receive no further treatment. Sentinel node-positive patients continue
      treatment according to randomization.

        -  Arm I: Within 8 weeks after surgery, patients undergo complete ALND.

        -  Arm II: Within 8 weeks after surgery, patients undergo axillary lymph node radiotherapy
           daily 5 days a week for 5 weeks.

      Patients in arm I may receive postoperative axillary irradiation if 4 or more nodes are
      positive and more than 1 axillary level is involved.

      Quality of life is assessed at baseline and then at 1, 2, 3, and 5 years.

      Patients are followed annually for 5 years.

      PROJECTED ACCRUAL: A total of 3,485 patients (1,394 sentinel node-positive and 2,091 sentinel
      node-negative) will be accrued for this study within 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Axillary recurrence rate</measure>
    <time_frame>from randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Shoulder function as assessed by arm function test questionnaire at baseline, 1, 3, and 5 years after surgery</measure>
    <time_frame>from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by Quality of Life Questionnaire Core 30 Items (QLQ-C30) and QLQ-BR25 at baseline, 1, 2, 3, and 5 years after surgery</measure>
    <time_frame>from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Axillary recurrence-free survival</measure>
    <time_frame>from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4813</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>axillary lymph node dissection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>complete axillary lymph node dissection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>axillary radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>axillary radiotherapy, daily for 5 days a week, for 5 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>axillary lymph node dissection</intervention_name>
    <arm_group_label>axillary lymph node dissection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lymphoscintigraphy</intervention_name>
    <arm_group_label>axillary lymph node dissection</arm_group_label>
    <arm_group_label>axillary radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <arm_group_label>axillary lymph node dissection</arm_group_label>
    <arm_group_label>axillary radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>axillary radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or &quot;triple diagnosis&quot; (palpation, mammogram or ultrasound, and
             cytology) confirmed operable invasive breast cancer

               -  T0-2, N0

               -  Diagnosis by excisional tumorectomy allowed

               -  Clinically occult invasive disease must be histologically confirmed

          -  Only 1 tumor in 1 breast

               -  Tumor between 5 and 50 mm in largest diameter, within 1 quadrant by mammogram,
                  ultrasound or MRI

                    -  Multifocal (i.e., within one quadrant and sharing the same histological
                       characteristics) is allowed

                    -  Multicentric (i.e., in different quadrants) breast cancer is not allowed

          -  Clinically negative axillary lymph nodes

          -  No metastatic disease

          -  No previous treatment of the primary breast tumor by neoadjuvant hormonal or systemic
             treatment

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Age:

          -  Any age

        Sex:

          -  Female

        Menopausal status:

          -  Not specified

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Other:

          -  Fit to undergo sentinel node biopsy, axillary clearance, breast surgery, and/or
             axillary radiotherapy

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study compliance

          -  No other prior malignancy except basal cell skin cancer or carcinoma in situ of the
             cervix

          -  Not pregnant

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiotherapy to axilla

        Surgery:

          -  No prior surgery to axilla

        Other:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emiel JT Rutgers</last_name>
    <role>Study Chair</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Mansel</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiff and Vale University Health Board - University Hospital of Wales, Cardiff</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cornelis Van De Velde</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Centre, Leiden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geertjan Van Tienhoven</last_name>
    <role>Study Chair</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam, Amsterdam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Grenoble - Hopital de la Tronche</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Degli Studi di Florence - Policlinico di Careggi</name>
      <address>
        <city>Firenze (Florence)</city>
        <zip>1 (50134)</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Ospedale San Giovanni Battista Molinette di Torino</name>
      <address>
        <city>Turin</city>
        <zip>10123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HagaZiekenhuis - Locatie Leyenburg</name>
      <address>
        <city>'s-Gravenhage</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Amstelland</name>
      <address>
        <city>Amstelveen</city>
        <zip>1180AH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum at University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gelre Ziekenhuizen - Lokatie Lukas</name>
      <address>
        <city>Apeldoorn</city>
        <zip>7334 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <zip>6800 TA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Group - Delft</name>
      <address>
        <city>Delft</city>
        <zip>NL 2600 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HagaZiekenhuis - Locatie Rode Kruis</name>
      <address>
        <city>Den Haag</city>
        <zip>2566 MJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Bronovo</name>
      <address>
        <city>Den Haag</city>
        <zip>2597AX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIJ Smellinghe</name>
      <address>
        <city>Drachten</city>
        <zip>NL-9200 DA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5602 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 EZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kennemer Gasthuis - Locatie EG</name>
      <address>
        <city>Haarlem</city>
        <zip>2000</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ropcke-Zweers Ziekenhuis</name>
      <address>
        <city>Hardenberg</city>
        <zip>7770</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis St. Jansdal</name>
      <address>
        <city>Harderwijk</city>
        <zip>3840 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum St. Radboud - Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Laurentius Ziekenhuis</name>
      <address>
        <city>Roermond</city>
        <zip>6043 CV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <zip>80-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology - Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>Sl-1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneve</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marmara University Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>81190</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M23 9LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Slovenia</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Straver ME, Meijnen P, van Tienhoven G, van de Velde CJ, Mansel RE, Bogaerts J, Demonty G, Duez N, Cataliotti L, Klinkenbijl J, Westenberg HA, van der Mijle H, Hurkmans C, Rutgers EJ. Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol. 2010 Feb 10;28(5):731-7. doi: 10.1200/JCO.2008.21.7554. Epub 2009 Dec 28.</citation>
    <PMID>20038733</PMID>
  </results_reference>
  <results_reference>
    <citation>Straver ME, Meijnen P, van Tienhoven G, van de Velde CJ, Mansel RE, Bogaerts J, Duez N, Cataliotti L, Klinkenbijl JH, Westenberg HA, van der Mijle H, Snoj M, Hurkmans C, Rutgers EJ. Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol. 2010 Jul;17(7):1854-61. doi: 10.1245/s10434-010-0945-z. Epub 2010 Mar 19.</citation>
    <PMID>20300966</PMID>
  </results_reference>
  <results_reference>
    <citation>Straver ME, Meijnen P, van Tienhoven G, et al.: Technical aspects of the sentinel node biopsy in the EORTC AMAROS sentinel node trial. [Abstract] 31st Annual San Antonio Breast Cancer Symposium, December 10-14, 2008, San Antonio, Texas. A-1006, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Meijnen P, Rutgers EJT, van de Velde CJH, et al.: EORTC 10981-22023 trial. AMAROS: after mapping of the axilla: radiotherapy or surgery? Trial update. [Abstract] Eur J Cancer 2 (Suppl 3): A-79, 79, 2004.</citation>
  </results_reference>
  <results_reference>
    <citation>Hurkmans CW, Borger JH, Rutgers EJ, van Tienhoven G; EORTC Breast Cancer Cooperative Group; Radiotherapy Cooperative Group. Quality assurance of axillary radiotherapy in the EORTC AMAROS trial 10981/22023: the dummy run. Radiother Oncol. 2003 Sep;68(3):233-40.</citation>
    <PMID>13129630</PMID>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>October 28, 2013</last_update_submitted>
  <last_update_submitted_qc>October 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

